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Primary immunodeﬁciency disorders (PID) represent a heterogeneous group of diseases
resulting from inherited defects in the development, maturation and normal function of
immune  cells; thus, turning individuals susceptible to recurrent infections, allergy, autoim-
munity, and malignancies. In this retrospective study, autoimmune diseases (AIDs), in
special systemic lupus erythematosus (SLE) which arose associated to the course of PID,
are described. Classically, the literature describes three groups of PID associated with SLE:
(1)  deﬁciency of Complement pathway components, (2) defects in immunoglobulin synthe-
sis,  and (3) chronic granulomatous disease (CGD). Currently, other PID have been described
with  clinical manifestation of SLE, such as Wiskott–Aldrich syndrome (WAS), autoimmune
polyendocrinopathy candidiasis ectodermal dystrophy (APECED), autoimmune lymphopro-
liferative syndrome (ALPS) and idiopathic CD4+ lymphocytopenia. Also we  present ﬁndings
from an adult cohort from the outpatient clinic of the Rheumatology Division of Universi-
dade Federal de São Paulo. The PID manifestations found by our study group were considered
mild in terms of severity of infections and mortality in early life. Thus, it is possible that some
immunodeﬁciency states are compatible with survival regarding infectious susceptibility;
however these states might represent a strong predisposing factor for the development ofimmune disorders like those observed in SLE.
© 2015 Elsevier Editora Ltda. All rights reserved.
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http://dx.doi.org/10.1016/j.rbre.2015.07.006
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Associac¸ão  de  imunodeﬁciência  primária  com  lúpus  eritematoso
sistêmico:  revisão  da  literatura  e  as  lic¸ões  aprendidas  pela  Divisão
de  Reumatologia  de  um  hospital  universitário  terciário  em  São  Paulo
Palavras-chave:
Doenc¸a autoimune
Imunodeﬁciência primária
Lúpus eritematoso sistêmico
Deﬁciência de anticorpos
r  e  s  u  m  o
As imunodeﬁciências primárias (IDP) representam um grupo heterogêneo de doenc¸as resul-
tantes de defeitos hereditários no desenvolvimento, maturac¸ão e func¸ão normal de células
do  sistema imunológico; assim, tornam os indivíduos suscetíveis a infecc¸ões recorrentes,
alergia, autoimunidade e doenc¸as malignas. Neste estudo retrospectivo, descrevem-se
doenc¸as  autoimunes (DAI), em especial o lúpus eritematoso sistêmico (LES), que surgiram
associadas ao curso das IDP. Classicamente, a literatura descreve três grupos de IDP associ-
adas ao LES: (1) deﬁciência de componentes da via do complemento, (2) defeitos na síntese
de  imunoglobulinas e (3) doenc¸a granulomatosa crônica (DGC). Na atualidade, outras IDP
têm  sido descritas como manifestac¸ões clínicas do LES, como a síndrome de Wiskott–Aldrich
(WAS),  a poliendocrinopatia autoimune-candidíase-distroﬁa ectodérmica (APECED), a sín-
drome linfoproliferativa autoimune (ALPS) e a linfocitopenia idiopática CD4+. Também são
apresentados achados de uma coorte de adultos do ambulatório da Divisão de Reumatolo-
gia  da Universidade Federal de São Paulo. As manifestac¸ões de IDP encontradas pelo nosso
grupo de estudo foram consideradas leves em termos de gravidade de infecc¸ões e mortal-
idade no início da vida. Assim, é possível que alguns estados de imunodeﬁciência sejam
compatíveis com a sobrevivência em relac¸ão à suscetibilidade infecciosa; no entanto, estes
estados podem representar um fator de predisposic¸ão forte para o desenvolvimento de
doenc¸as  imunológicas, como observado no LES.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
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rimary immunodeﬁciency disorders (PID) represent a hetero-
eneous group of diseases resulting from inherited defects in
he development, maturation and normal function of immune
ells. PID often have an important genetic basis leading
o different immune disorders associated with infections,
utoimmune diseases and other malignancies in patients.1
ince these are congenital conditions, usually with well-
eﬁned genetic defects and mendelian inheritance, children
re the most predominant patients. On the other hand,
utoimmune diseases (AIDs) have a complex multifactorial
olygenic etiology in which environmental triggers play an
mportant role in their pathogenesis and represent a group
f more  than 70 known diseases.2 Remarkably, AIDs represent
ne of the most common clinical phenotypes of many  forms
f PID, only overcome by the frequency of infections.3
Systemic lupus erythematosus (SLE) is a multi-organ
utoimmune disease characterized by a range of clinical
anifestations that predominantly affects women  in repro-
uctive age. In SLE, polyclonal hypergammaglobulinemia and
ultiple autoantibodies are produced predominantly against
uclear antigens. These autoantibodies deposit on several
rgans, including kidneys, skin and joints, causing severe
nﬂammation.4 Although SLE patients have hypergamma-
lobulinemia, they often present severe infections, especially
hile receiving immunosuppressive treatment.
Infections by opportunistic pathogens are commonly
een in patients with PID.5 These infections, eitherclinical or subclinical, may represent the primary trigger
for the development of autoimmunity. In genetically pre-
disposed individuals, chronic exposure to environmental
factors can promote the development of autoantibodies
many  years before the disease onset. Patients with SLE
present an increased susceptibility to infection in pre-
clinical phase of disease.6 Classically, the literature describes
three groups of PID associated with SLE: (1) deﬁciency
of Complement pathway components7; (2) selective and
partial defects in immunoglobulin synthesis (particularly
isolated IgA and IgM deﬁciencies)8,9; and (3) chronic gran-
ulomatous disease (CGD).9–12 However, among clinical
observations, several other PID may also occasionally be
associated with SLE or SLE-like syndrome manifestations.
These include Wiskott–Aldrich syndrome (WAS),13 autoim-
mune polyendocrinopathy candidiasis ectodermal dystrophy
(APECED),14 autoimmune lymphoproliferative syndrome
(ALPS),15 idiopathic CD4+ lymphocytopenia (ICL),16 partial
T cell immunodeﬁciency and hyper-immune dysregula-
tion (including autoimmunity, inﬂammatory diseases and
elevated IgE production).17
Our group has reported that a broad fraction of juve-
nile SLE patients present one of the several forms of PID.18
More  recently, we documented that 28% of a consecutive
cohort of 300 adult SLE patients present some form of PID,
mainly related to immunoglobulin deﬁciency. In this review,
we describe the various PID associations with SLE or SLE-like
manifestations and also our experience from the outpatient
clinic of the adult Rheumatology Division at Universidade Fed-
eral de São Paulo.
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Classical  and  non-classical  PID  associated
with  SLE
PID are a heterogeneous group of diseases characterized
by increased susceptibility to multiple and recurrent infec-
tions caused by virulent and non-virulent microorganisms.
The literature ranks PID in classical and non-classical forms.
Classical PID are deﬁned on the basis of an overt immuno-
logic phenotype, often leading to the identiﬁcation of the
disease-causing gene. The expert committee on Primary
Immunodeﬁciency of the International Union of Immuno-
logical Societies (IUIS) recently updated the classiﬁcation of
human classical PID.19 Non-classical PID are deﬁned on the
basis of a speciﬁc though unremarkable clinical phenotype,
and never have been classiﬁed as a fully distinct phenotype out
of PID classiﬁcation. Additionally, they have not been included
in the updated classiﬁcation of PID, compiled by the ad hoc
Expert Committee of the IUIS.20 However, the fact that non-
classical PID may not be associated with recurrent infections
does not guarantee that these diseases do not predispose
the development of autoimmune disorders. Therefore, in this
paper, we  describe the major classical and non-classical PID
associated to SLE.
Complement  deﬁciencies
The Complement system is composed by a group of plasma
and surface cell-proteins with important role in innate
and acquired humoral immune system, responsible for the
destruction of microbial agents and clearance of circulating
immune complexes.21 In SLE, the deposition of immune com-
plexes containing multiple autoantibodies and activation of
the Complement system mediate tissue damage.4 Paradox-
ically, deﬁciencies in components of early elements of the
classical pathway (C1q, C1r, C1s, C4, and C2) are strongly asso-
ciated with the development of SLE. In addition, deﬁciency
in components of the late common pathway (C5, C6, C7, C8a
and C8b) as well as some elements of the alternative path-
way (C3 and Factor I) are only occasionally associated with SLE
(Table 1).19 Genetic deﬁciencies of these components might
contribute towards SLE pathogenesis by decreasing immune
complex clearance capacity. The literature is controversial
in respect to mannose-binding lectin (MBL)22,23 and antibod-
ies against MBL24 in the pathogenesis of SLE. Some authors,
and this includes our group, have described the presence of
increased MBL  deﬁciency in SLE patients (unpublished data).
However, further studies should be conducted for a better elu-
cidation of this association with SLE.
Defects  in  immunoglobulin  synthesis  (antibody
deﬁciencies)
Antibody deﬁciencies also referred as immunoglobulin deﬁ-
ciencies, represent a group of diseases (immune system disor-
ders) characterized by low or absent levels of immunoglobulin
in the blood. Immunoglobulins (Ig) are large y-shaped gly-
coprotein molecules produced by B cells that detect, bind
and neutralize foreign substances (like bacteria, viruses,
fungi, toxins and allergens). They also have the capability 2 0 1 6;5 6(1):58–68
to signal immune cells to eliminate foreign substances. Anti-
body deﬁciencies represent a group of diseases and are
considered the most common type of primary immune deﬁ-
ciencies in humans. Due to the fact that protective levels of
IgG that are passively acquired by the newborns from the
mother decreases during the ﬁrst year of life, symptoms of
this group of diseases only become symptomatic at the end
of the ﬁrst year of life. The spectrum of antibody deﬁciencies
is broad, ranging from the absence of B cells and serum Igs
(most severe type of antibody deﬁciency) to selective antibody
deﬁciency with normal serum levels of total immunoglobulin.
In addition to increased susceptibility to infections, clinical
presentation of antibody deﬁciencies may also include other
disease processes (e.g., autoimmunity and malignancies).
Common  variable  immunodeﬁciency  disorders
Common variable immunodeﬁciency (CVID) is a heteroge-
neous group of primary antibody deﬁciencies diagnosed in
humans, with broad clinical spectrum. CVID patients present
history of hypogammaglobulinemia, recurrent respiratory
tract infections, but the clinical spectrum may include autoim-
mune phenomena, bowel inﬂammatory or infectious disease,
and granulomatous disease which can affect liver, spleen
and lungs.25 It has been postulated that persistent antigen
stimulation, recurrent tissue damage, defective clearance of
immune complexes and immune dysregulation contribute
toward the development of autoimmunity, including SLE, but
more  frequently autoimmune cytopenia and endocrinopa-
thy. Fernandez-Castro et al. described a series of 18 patients
with SLE and CVID. Interestingly, up to 67% of them had
the autoimmune disease controlled after the development of
the immunodeﬁciency.26 Genetic abnormalities described in
CVID include defects in the inducible co-stimulator (ICOS),
the membrane activator and calcium-modulator interactor
(TACI), the B-cell activating factor receptor (BAFF-R), CD19,
CD20 and CD81 (Table 2).19 Although CVID has been described
in patients after the diagnosis of SLE,26,27 immunosuppress-
ive agents used for SLE treatment can be the very cause of
hypogammaglobulinemia development, turning the deﬁnitive
diagnosis of CVID into a difﬁcult task, since the diagnosis
of CVID depends on exclusion of all other known causes of
hypogammaglobulinemia.
Selective  IgA  deﬁciency
Selective IgA deﬁciency (SIgAD) is the most common PID (ran-
ging from 1:400 to 1:3000).9 Since the majority of patients
are asymptomatic, this disorder may be unnoticed during
childhood or even on adult phase. These patients present
recurrent sino-pulmonary infections, allergy, gastrointesti-
nal disease, endocrinopathy, malignancy and autoimmunity
(Table 2). Eventually, patients with SIgAD evolve to CVID. SIgAD
is frequently found in patients previously diagnosed with
autoimmune disease such as Graves’ disease (GD), type 1 dia-
betes (T1D), celiac disease (CD), myasthenia gravis (MG), SLE,
28and rheumatoid arthritis (RA). A high prevalence of SIgAD
was described in juvenile SLE (5.2%) and in adult onset SLE
(2.6%).8 It is hypothesized that the absence of mucosa IgA may
reduce clearance and neutralization of antigen and pathogen,
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Table 1 – Complement deﬁciencies associated with SLE or SLE-like manifestation.
Disease Association features and autoimmune manifestation Inheritance Defective gene OMIM number
C1q deﬁciency SLE-like syndrome, rheumatoid syndrome,
infections
AR C1QA  120550
C1QB 601269
C1QC 120575
C1r deﬁciency SLE-like syndrome, rheumatoid syndrome, multiple
autoimmune diseases, infections
AR  C1r 216950
C1s deﬁciency SLE-like syndrome; multiple autoimmune diseases AR C1s 120580
C4 deﬁciency SLE-like syndrome, rheumatoid syndrome,
infections
AR  C4A 120810
C2 deﬁciency SLE-like syndrome, vasculitis, atherosclerosis,
polymyositis, pyogenic infections;
glomerulonephritis
AR  C2 217000
C3 deﬁciency Life threatening pyogenic infections; SLE-like
disease; glomerulonephritis; atypical
hemolytic–uremic syndrome
AR  C3 120700
C5 deﬁciency Neisseria infection, SLE AR  C5 or C5 120900
C6 deﬁciency Neisseria infection, SLE AR C6 217050
C7 deﬁciency Neisseria infection, SLE, vasculitis AR C7 217070
C8a deﬁciency Neisseria infection, SLE AR C8 120950
C8b deﬁciency Neisseria infection, SLE AR C8 120960
Factor I deﬁciency Recurrent pyogenic infections, glomerulonephritis,
SLE; hemolytic–uremic syndrome; severe
pre-eclampsia
AR  CFI 610984
itanc
w
e
u
H
H
i
b
t
g
i
k
(
c
e
d
a
p
a
t
c
I
I
l
n
c
r
r
r
pAD, autosomal dominant inheritance; AR, autosomal recessive inher
hich serve as triggers for breaking immune tolerance. How-
ver, the association between SIgAD and SLE is not completely
nderstood yet.
yper-IgM  syndrome
yper-IgM syndrome (HIGM) is a non-classical PID character-
zed by antibody deﬁciency with the absence of IgG and IgA
ut normal or increased IgM levels. Different genetic muta-
ions can cause this PID; including mutation of CD40 ligand
ene (CD40LG gene, X-linked HIGM), CD40 gene, Activation-
nduced DNA-cytidine deaminase gene (AICDA gene, also
nown as AID) and uracil DNA glycosylase gene (UNG)
Table 2).19,29 Patients with HIGM usually present during
hildhood opportunistic infections and autoimmune dis-
ases (autoimmune cytopenia, nephritis, inﬂammatory bowel
isease, autoimmune hepatitis, arthritis, hypothyroidism
nd SLE). Autoimmune manifestation are more  frequent in
atients that present HIGM due to mutations in AID, however,
utoimmune manifestations have also been reported in other
ypes of HIGM.29,30 There are very few cases reported on the
oexistence of SLE and AID or UNG associated Hyper-IgM.31
solated  IgG  subclass  deﬁciency
gG subclass deﬁciency is deﬁned as a serum IgG subclass
evel that is more  than two standard deviations below the
ormal mean for age. IgG subclass deﬁciency can be asso-
iated with recurrent infections of the upper and lower
32espiratory tracts. Pathogens are generally limited to bacte-
ia and respiratory viruses. Because IgG2 is important in the
esponse to polysaccharide antigens, IgG2 subclass-deﬁcient
atients typically have infections with Haemophilus inﬂuenza ore; SLE, systemic lupus erythematosus.
Streptococcus pneumoniae.33 In adults, deﬁciency of IgG3 sub-
class is the most common, whereas in children IgG2 is the
most prevalent IgG subclass deﬁciency. IgG subclass deﬁciency
may be seen in conjunction with other primary immune
deﬁciency disorders, such as ataxia-telangiectasia and IgA
deﬁciency.34 An IgG subclass deﬁciency might occur as an iso-
lated single IgG subclass deﬁciency or as a deﬁciency of two or
more IgG subclasses. The literature describes sporadic cases
of autoimmune manifestation in patients with IgG subclass
deﬁciency,35–38 like IgG1,39 IgG440 and combined IgG2 and IgG4
subclass deﬁciency.41 The prevalence might be higher, how-
ever those cases might go unnoticed, since IgG subclasses
serum level determination is not included in routine eval-
uation of SLE patients. Jesus et al. (2011) also showed the
coexistence of IgG2 deﬁciency in 5.5% of the juvenile SLE
patients studied, representing 21% of all PID cases in their
series.18
IgM  deﬁciency
The IgM deﬁciency (IgMD) has been reported in patients
with several forms of autoimmune diseases. One reported
case describes a 15-year-old female presenting a 22q11.2
deletion syndrome (partial DiGeorge Syndrome) who  pre-
sented recurrent and chronic otitis media, developmental
delay, not associated with any other immunologic defects.42
Patients with IgMD and 22q11.2 deletion syndrome may
present sinopulmonary recurrent infections, which typically
respond to conventional antibiotic therapy without the need
of prolonged antibiotic use or intravenous immunoglobu-
lin therapy (IVIg).43 In IgMD patients, recurrent respiratory
tract infections, asthma, allergic rhinitis, vasomotor rhinitis,
angioedema, and anaphylaxis have been described.44 Patients
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Table 2 – Primary immunodeﬁciencies frequently associated with SLE or SLE-like manifestation.
Disease Association features and autoimmune
manifestation
Inheritance Defective gene OMIM
number
Predominantly antibody deﬁciencies
CVID Hypogammaglobulinemia, recurrent
chronic infections, inﬂammatory
bowel disease, autoimmune hemolytic
anemia, thrombocytopenia,
rheumatoid arthritis, pernicious
anemia, diabetes mellitus,
polymyositis, SLE
AR  ICOS 604558
AR CD19 107265
AR CD81 186845
AR CD20 112210
AD, AR TNFRSF13B  (TACI) 604907
AR TNFRSF13C  (BAFF-R) 606269
SIgAD Usually asymptomatic; may have
recurrent infections with poor antibody
responses to carbohydrate antigens,
rheumatoid arthritis, diabetes mellitus,
SLE
Variable Unknown
HIGM Decreased IgG, normal to elevated
IgM, sinopulmonary infections,
lymphoid hyperplasia, diabetes
mellitus, autoimmune hepatitis,
rheumatoid arthritis, inﬂammatory
bowel disease, uveitis, idiopathic
thrombocytopenia purpura,
autoimmune hemolytic anemia, SLE
XL CD40LG 300386
AR CD40 109535
AR AICDA 605257
AR UNG 191525
Isolated IgG subclass deﬁciency Reduction in one or more IgG subclass,
usually asymptomatic; a minority may
have poor antibody response to speciﬁc
antigens and recurrent viral/bacterial
infections
Variable Unknown
SIgMDa Recurrent respiratory tract infections,
asthma, allergic rhinitis, vasomotor
rhinitis, angioedema, and anaphylaxis,
glomerulonephritis, SLE
Unknown
Congenital defects of phagocyte number, function or both
CGD Recurrent suppurative microbial
infections, chronic inﬂammation with
granuloma formation, inﬂammatory
bowel disease, SLE
XL  CYBB 306400
AR CYBA 233690
AR NCF1 233700
AR NCF2 233710
AR NCF4 601488
Well-deﬁned syndromes with immunodeﬁciency
WAS Thrombocytopenia with bleeding
diathesis, eczema, recurrent infections,
autoimmune hemolytic anemia,
vasculitis, inﬂammatory bowel disease,
glomerulonephritis, rheumatoid arthritis,
SLE
XL  WAS 301000
Syndromes with autoimmunity
APECED Autoimmunity of parathyroid, adrenal,
and other endocrine organs, chronic
candidiasis, vitiligo, hepatitis
autoimmune, diabetes mellitus
AR  AIRE 240300
ALPS-FAS Splenomegaly, adenopathies,
autoimmune cytopenias, lymphoma,
defective lymphocyte apoptosis
AD,  AR TNFRSF6  601859
ALPS-FASLG Splenomegaly, adenopathies,
autoimmune cytopenias, defective
lymphocyte apoptosis
AD,  AR TNFSF6 134638
ALPS-CASP10 Adenopathies, splenomegaly,
autoimmunity, defective lymphocyte
apoptosis
AD CASP10 603909
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Table 2 – (Continued)
Disease Association features and autoimmune
manifestation
Inheritance Defective gene OMIM
number
Caspase 8 defect Adenopathies, splenomegaly, recurrent
bacterial/viral infections, defective
lymphocyte apoptosis,
hypogammaglobulinemia
AD  NRAS 164790
Others
ICLa CD4+ lymphocytopenia, opportunistic
infections, antiphospholipid syndrome,
psoriasis, Hashimoto’s thyroiditis, Graves
disease, ulcerative colitis, vitiligo and SLE
UNC119
AD, autosomal dominant inheritance; AR, autosomal recessive inheritance; XL, X-linked inheritance; CVID, common variable immunodeﬁ-
ciency; SIgMD, selective deﬁciency IgM; SIgAD, selective deﬁciency IgA; HIGM, hyper-IgM syndrome; CGD, chronic granulomatous disease;
WAS, Wiskott–Aldrich Syndrome; APECED, autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy; ALPS, autoimmune
a; SLE
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a Non-classic PID.
ay present antinuclear antibodies (ANA).45 Few reports have
ocused their analysis on selective IgM deﬁciency however a
etailed pathogenesis of this disorder still remains to be care-
ully analyzed. A study on a case report of a 37-year-old woman
ho  presented selective IgM deﬁciency with concurrent IgG4
eﬁciency, various dermal symptoms and a bronchial polyp,
erves as an observation of a not very clear association
etween a solitary polyp and IgM deﬁciency, however sug-
estions have been made for repeated IgM deﬁciency-related
irway infections as a probable etiological factor for the
nﬂammatory polyp.46 It is speculated that the reduction of
ecreted IgM production is related to the risk of progression
f autoimmune diseases, such as autoimmune glomeru-
onephritis and SLE in humans. In fact, a few case reports
r series show association of this disorder with autoimmune
heumatic diseases, including SLE,44,47 especially in patients
ith disease of long duration.48 Interestingly, disease remis-
ion did not correlate with elevation of IgM serum levels,
ndicating a deeper dysregulation of the immune system.
ongenital  defects  of  phagocyte
hagocytes such as monocytes/macrophages as well as gra-
ulocytes are the cells that engulf and destroy ingested
athogens during a process denominated phagocytosis. In cer-
ain conditions, either the number of phagocytes is reduced
r their functional capacity is impaired.49 Almost all PID
ue to phagocyte defects are a consequence of inherited
utations affecting the innate immune system. Most of
hese PID patients are identiﬁed at very young age based
n their clinical phenotype of susceptibility to normally
onpathogenic bacteria or fungi, and in some cases, the infec-
ious agents point to the disorder.50 Defects of these cells
nclude decreased number of neutrophils caused by defects
n granulocyte development or capability to exit into the cir-
ulation leading to neutropenia; or due to the presence of
utoantibodies or isoantibodies directed against neutrophil
embrane antigens. Other defects include abnormalities
n granulocyte killing ability, opsonic capability secondary
o deﬁciencies of antibody and complement factors, and
hemotaxis.50, systemic lupus erythematosus.
Chronic  granulomatous  disease
Chronic granulomatous disease (CGD) is a primary immuno-
deﬁciency of phagocytes, with X-linked or autosomal recessive
inheritance. The X-linked form presents mutation in CYBB
gene that encodes the heavy chain of cytochrome b558, or gp91-
phox (56% of cases), an electron transport protein responsible
for the oxidative burst of phagocytes. These patients present
severe and recurrent infections of skin, respiratory system,
gastrointestinal tract and adjacent lymphonodes, pancreas,
bones and central nervous system. Persistence of microorgan-
isms in phagolysosomes leads to granuloma formation that
causes obstruction along the gastrointestinal or urinary tract.
In the autosomal recessive form, genes affected include the
other components of NADPH oxidase system: NCF1 (adapter
protein p47-phox, 33% of cases); NCF2 (activator protein p67-
phox, 5% of cases); and NCF4 (p40-phox), 6% of cases.51
Patients with X-linked form present severe infections in the
ﬁrst year of life, and patients with the autosomal recessive
form of CGD have less severe clinical manifestation, with late
onset symptoms. Oral ulcers and autoimmune manifestation
(antiphospholipid syndrome, recurrent pericardial effusion,
juvenile idiopathic arthritis, IgA nephropathy, cutaneous and
systemic lupus erythematosus, and autoimmune pulmonary
disease) are frequently seen in patients with CGD.52 Addi-
tionally, the mother’s status of carrier of the affected gene
is associated to higher frequency of discoid lupus lesions.11
X-linked form can also present McLeod phenotype (a genetic
disorder that may affect the blood, brain, peripheral nerves,
muscle and heart, caused by a variety of recessively inherited
mutations in the XK gene on the X chromosome, responsible
for producing the Kx protein, a secondary supportive protein
for the Kell antigen on the red blood cell surface, with compen-
sated hemolysis, acanthocysis and progressive degenerative
neuromuscular disorders).53
Well-deﬁned  PID  and  PID  syndromes  associated  with  SLEWithin the clinical framework of PID, the most common fea-
ture besides susceptibility to infections is represented by
autoimmune manifestations. Recent advances in both ﬁelds
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have lead to the identiﬁcation that associations of PID with
AIDs are more  frequent than previously appreciated.5,54,55 It
became evident that different types of PID display consistent
associations with distinct autoimmune disorders (including
homozygous deﬁciencies of early components of the classical
Complement pathway, selective and partial immunoglobu-
lin deﬁciencies, particularly isolated IgA and IgM deﬁciencies,
and X-linked and autosomal forms of chronic granulomatous
disease), allowing the perception that the study of the associ-
ation between PID and AIDs represents a unique opportunity
for new insights and a better understanding of the pathophy-
siology as well as the genetic basis of autoimmunity.
Wiskott–Aldrich  syndrome
The Wiskott–Aldrich syndrome (WAS) is a PID caused by muta-
tion in the WAS gene, that encodes a protein associated to
the process of cell locomotion, immunological synapse for-
mation, apoptosis and phagocytosis. Mutations in the WAS
gene can lead to severe clinical manifestations (classical
WAS), light manifestations (X-linked thrombocytopenia/XLT)
and X-linked neutropenia (neutropenia and thrombocyto-
penia without myelodysplasia or immunodeﬁciency). Patients
usually present elevated IgA and IgE serum levels, normal IgG,
and slightly decreased IgM. The cytotoxic activity of NK cells
and CD8 T lymphocytes is impaired. Infections are common
since six months of age, with the development of otitis media,
sinusitis, pneumonia and diarrhea. Viral infections are com-
mon, especially for chickenpox, herpes simplex and molluscum
contagiosum. Clinical presentation is normally variable, with
symptoms appearing soon after birth or in early life. Patients
with WAS have small platelets, lacking speciﬁc granules,
reduced numbers of organelles in the cytoplasm, defective
platelet aggregation and ineffective thrombocytopoiesis. The
appearance of petechiae, bruising, bleeding and severe cases
of thrombocytopenia hemorrhage of central nervous system
are frequent.56,57 Eczema, recurrent infections, autoimmune
diseases (hemolytic anemia, vasculitis, nephropathy, purpura
resembling Henoch–Schonlein, inﬂammatory bowel disease,
SLE, and IgA nephropathy) and malignancies (lymphoma,
leukemia) are not rare manifestations.13,58
Autoimmune  polyendocrinopathy  with  candidiasis
and  ectodermal  dystrophy
Autoimmune polyendocrinopathy candidiasis and ectoder-
mal  dystrophy (APECED) or autoimmune polyendocrine
syndrome type I (APS1) is a PID that harbors autoimmunity
within its very essence. There is a wide variation in the clinical
features and course of APECED, even among patients sharing
the same mutation in the autoimmune regulator gene (AIRE),
involved in the disorder and whose encoded protein is respon-
sible for presenting several self-antigens in thymus medullae.
While speciﬁc mutations in the AIRE gene have not been
associated with disease phenotype, associations with speciﬁc
HLA haplotypes have been noted for some of the autoim-
mune manifestations of APECED, including alopecia, T1D,
and Addison’s disease. Chronic mucocutaneous candidiasis,
hypoparathyroidism, and adrenocortical failure are the clas-
sic triad of ﬁndings that characterize this syndrome.59 2 0 1 6;5 6(1):58–68
Other autoimmune endocrinopathies can be present, includ-
ing insulin-dependent diabetes mellitus, autoimmune thy-
roiditis, premature ovarian failure, and hypergonadotropic
hypogonadism. Immune-mediated gastrointestinal diseases,
autoimmune dermatologic conditions, ectodermal dystrophy,
keratoconjunctivitis, iridocyclitis, hemolytic anemia, oral and
esophageal cancers, chronic hepatitis, nephritis, cholelithiasis
and SLE have also been seen associated to APECED.60,61
Autoimmune  lymphoproliferative  syndrome
Autoimmune lymphoproliferative syndrome (ALPS) is an
autosomal dominant disorder caused by abnormalities
in Fas-mediated lymphocyte apoptosis, with clinical fea-
tures of splenomegaly and lymphadenopathy, and various
autoimmune manifestations. ALPS caused by heterozygous
mutations in the Fas gene (TNFRSF6; ALPS Type Ia) make
up the majority of identiﬁed cases. ALPS caused by muta-
tions in other factors involved in the Fas apoptosis pathway
have been identiﬁed, including FasL (TNFSF6; ALPS Type Ib),
Caspase 8 (NRAS) and Caspase 10 (CASP10) (the latter two,
ALPS Type II). There is also a subgroup of patients with
ALPS phenotype, abnormal Fas-mediated apoptosis, but no
identiﬁed mutation in the Fas pathway (ALPS Type III).62,63
Immunological abnormalities characteristic of ALPS include
the presence of increased number of circulating CD4−CD8−
/+ lymphocytes (double negative), as well as T- and B-
cell lymphocytosis and polyclonal hypergammaglobulinemia.
Autoimmune hemolytic anemia and immune thrombocy-
topenia are the most common autoimmune features seen
in ALPS. Autoimmune neutropenia and the presence of
anticardiolipin antibodies are also often present, whereas
autoimmune hepatitis, uveitis, and glomerulonephritis are
much less common manifestations in these patients.63 The
literature describes a case of SLE-like syndrome in a 59-year-
old woman with arthritis, low fever, intermittent hypotension,
confusion, macular skin rash with telangiectasia and perivas-
cular lymphocyte inﬁltration, cytopenia without abnormal
cells, hepatosplenomegaly, pericardial and pleural effusion,
cervical lymph node enlargements and diffuse large B cell
lymphoma. This patient was described with autoimmune
lymphoproliferative syndrome-like syndrome.15
Idiopathic  CD4+ lymphocytopenia
Idiopathic CD4+ lymphocytopenia (ICL) is a non-classical
PID characterized by a T CD4+ lymphocyte cell count below
300/mm3 or 20% of total T lymphocyte cell count in the
absence of identiﬁed cause, including human immunodeﬁ-
ciency virus (HIV) or human lymphocytotropic virus (HTLV)
infections, and absence of causative drug.64 Recently, a
mutation in patients with ICL was described,65 but fur-
ther studies are needed for deﬁnitive conclusion since the
etiology still remains poorly understood and inadequately
deﬁned. Mechanisms implicated in CD4+ lymphocyte reduc-
tion may include decreased production, increased destruction,
and tissue sequestration of these cells. Clinical presenta-
tion includes Cryptococcus spp. opportunistic infections and
non-mycobacterial infections. Presence of malignancies is
common, frequently due to opportunistic pathogens with
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Table 3 – Autoimmune diseases, primary
immunodeﬁciencies and infections found in 300
Brazilian SLE patients.
Autoimmune rheumatic disease n = 32 (10.6%)
Antiphospholipid syndrome n = 16 (5.3%)
Sjögren syndrome n = 7 (2.3%)
Systemic sclerosis n = 4 (1.3%)
Rheumatoid arthritis n  = 4 (1.3%)
Polymyositis n = 2 (0.6%)
Psoriatic arthritis n = 1 (0.3%)
Non-rheumatic autoimmune disease n = 20 (6.6%)
Hypothyroidism n = 15 (5%)
Psoriasis n = 3 (1%)
Vitiligo n = 3 (1%)
Primary biliary cirrhosis n = 1 (0.3%)
IgA nephropathy n = 1 (0.3%)
Primary immunodeﬁciency disease (Classical and non-Classical)
n = 84 (28%)
SIgMDa n = 24 (8%)
SIgAD n = 3 (1%)
Def IgG n = 1 (0.3%)
Def IgG1 n = 5 (1.6%)
Def IgG2 n = 40 (13.3%)
Def IgG3 n = 24 (8%)
Def IgG4 n = 11 (3.6%)
CGD gene carrier n = 1 (0.3%)
Infections n = 28 (9.33%)
Airway infection n = 9 (3%)
Urinary tract infection n = 15 (5%)
Furunculosis n = 3 (1%)
Herpes simplex n = 2 (0.6%)
Herpes zoster n = 2 (0.6%)
Tuberculosis n = 1 (0.3%)
Hanseniasis n = 1 (0.3%)
SIgAD, selective IgA deﬁciency; SIgMD, selective IgM deﬁciency.r e v b r a s r e u m a t
n oncogenic potential (human papillomavirus/HPV, Kaposi’s
arcoma by HHV8+).66,67 Autoimmune diseases observed in
 series of 39 cases of ICL include SLE, antiphospholipid
yndrome, psoriasis, Hashimoto’s thyroiditis, Graves disease,
lcerative colitis and vitiligo.68,69
linical  characteristics  of  patients  with  SLE  and
ID manifestations  followed  by  the  outpatient
linic  of  the  Rheumatology  Division
t Universidade  Federal  de  São  Paulo
etween 2009 and 2011, our group followed 315 consecutive
dult SLE patients at the Rheumatology Division outpatient
linic of the University Hospital of Universidade Federal de
ão Paulo. The purpose of the study was to systematically
rack a comprehensive array of PID in a large cohort. Once the
isease activity could inﬂuence the results, all patients were
ollowed until achieving disease quiescence. Fifteen patients
emained with active disease throughout the follow-up and
ere, therefore, excluded from the analysis. Patients followed
ere predominantly females (16 males and 284 females),
ith 39.58 ± 12.54 mean years-old (age ranging from 18 to
1 years), mean disease duration of 10.74 ± 8.15 years (disease
uration from 1 to 53 years) and mean age at SLE onset of
8.79 ± 10.89 years-old (SLE onset from 3 to 69 years). Total
requency of infections in SLE patients was 28 (9.33%). Those
atients were classiﬁed using the warning signals for pri-
ary  immunodeﬁciency recently revised.70 Unfortunately the
ross-sectional design of our study could not allow the calculi
f mortality rate. Nine patients had recurrent airway infec-
ions, whereas 15 presented recurrent urinary tract infections
nd three, skin furunculosis. Two patients presented recurrent
ral/genital Herpes simplex and two others had Herpes zoster
nfection. Additionally, two patients manifested mycobacte-
ial infection: one had pulmonary tuberculosis and the other
anseniasis (Table 3). In the present series, other autoimmune
iseases were observed in 47 individuals (15.66%) [including
heumatic autoimmune diseases (n = 32) and non-rheumatic
utoimmune diseases (n = 20)], some of which presenting more
han one autoimmune condition. Eighty-four patients (28%)
ere identiﬁed with immunity defects compatible with clas-
ical PID (Table 3), and in four patients (1.3%) more  than
ne associated PID were identiﬁed (SIgAD + IgG2; SIgAD + IgG4;
gMD + IgG2 in 2 patients). Differently from our results, the lit-
rature describes one case of SIgMD accompanied with IgG4
eﬁciency (Ideura et al.46). Interestingly, one patient presented
 respiratory burst proﬁle impaired enough to be classiﬁed
s a CGD gene carrier but no patient presented the proﬁle
ompatible with full-blown disease. Our clinical and labo-
atory ﬁndings have demonstrated that the PID observed
n SLE patients are considered mild in terms of severity of
nfections and mortality. We speculate that those PID are com-
atible with apparently normal life, but that the consequent
ong-standing antigenic burden may be a risk factor for the
evelopment of AIDs, represented in this cohort by SLE. Gen-
rally, severe forms of PID are diagnosed at early stage of
ife, while non-severe or mild forms of PID manifestations are
ostly asymptomatic.20 We  found that 28% of our cohort of
dult SLE patients was constituted by mild PID which allowed
 longer survival rate, passing unnoticed during childhood.a Non-classic PID.
This could possibly explain the absence of illnesses such as
CVID, CGD and HIGM. Surprisingly, in our cohort the presence
of IgMD, a non-classical form of PID, was very frequent. We  also
observed in our cohort a large number of SLE patients with IgG
subclass deﬁciency, while literature reports only some cases
of isolated deﬁciency of IgG2 and IgG4.18,41,71,72 In our study,
all patients with IgG4 deﬁciency and 75% of those with IgG3
deﬁciency had lupus nephropathy, which is above the ∼50%
frequency in the whole cohort. In addition, patients with IgMD
presented lower frequency of oral ulcers. Apart from IgG4 and
IgG3 deﬁcient patients, the remaining patients did not present
a much severe phenotype regarding the presence of infections
and lupus manifestations.
Our ﬁndings regarding the association of immunoglobu-
lin deﬁciency and the development of autoimmune disease
could be partially explained based on the ‘waste disposal’
hypothesis, which postulates that defects on the clearance
of dying cells increases the risk of developing autoimmu-
nity since these cells provide the source of auto antigens
7responsible for driving autoantibody production in SLE. Addi-
tionally, because SLE is associated with a humoral exacerbated
response, the presence of a primary dysfunction of B lym-
phocytes may be considered as a predisposing factor for
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unbalanced IgG subclasses synthesis, which may be consid-
ered as a factor for the development of SLE. These results
suggest that mild immunologic defects might be compatible
with patient survival, but at the expense of some chronic over-
load and future consequences to the immune system, which
could lead to the development of immune disorders character-
istic of SLE in the adulthood. The study ﬁndings give ground to
further investigations that could deeply explore the participa-
tion of PID in the pathogenesis of SLE and other autoimmune
rheumatic and non-rheumatic disease.
Conclusion
PID are a group of monogenic diseases in which mutations
of certain genes can lead to increased susceptibility to infec-
tions but may also result in loss of central and/or peripheral
tolerance. Therefore, AIDs are common among patients with
a diverse array of PID. Immunoglobulin deﬁciency forms a
peculiar group of PID, in which the inheritance appears to be
polygenic and there is a wide severity spectrum, with mild
forms that usually remain unnoticed. Our ﬁndings in adult
patients with SLE suggest that AIDs can present a higher fre-
quency of less severe forms of PID without severe infections.
The presence of some forms of PID was associated with cer-
tain phenotypic peculiarities in SLE patients. The literature
and our ﬁndings show that PID and AIDs frequently coexist
and patients with autoimmune diseases should be carefully
monitored for the presence of PID and vice versa.
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